Page last updated: 2024-11-06

3,3',5-triiodothyroacetic acid and Dyslipidemias

3,3',5-triiodothyroacetic acid has been researched along with Dyslipidemias in 1 studies

tiratricol : A monocarboxylic acid that is (4-hydroxy-3,5-diiodophenyl)acetic acid in which the phenolic hydroxy group has been replaced by a 4-hydroxy-3-iodophenoxy group. It is a thyroid hormone analogue that has been used in the treatment of thyroid hormone resistance syndrome.

Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.

Research Excerpts

ExcerptRelevanceReference
" 3,5-diiodothyronine (T2) has been used with success in rat models of dyslipidemia and NAFLD, but the outcome of a clinical trial with a synthetic T2 analogue was disappointing."5.05Thyroid Hormone Analogues: An Update. ( Zucchi, R, 2020)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Zucchi, R1

Reviews

1 review available for 3,3',5-triiodothyroacetic acid and Dyslipidemias

ArticleYear
Thyroid Hormone Analogues: An Update.
    Thyroid : official journal of the American Thyroid Association, 2020, Volume: 30, Issue:8

    Topics: Acetates; Anilides; Animals; Central Nervous System Diseases; Clinical Trials as Topic; Diiodothyron

2020